Pfizer Inc. PFE is expected to get Food and Drug Administration approval for use of its COVID-19 vaccine in children aged 12 to 15, according to a report late Monday. Unnamed federal officials told The New York Times that the approval could come as early as late this week. Pfizer’s vaccine, which it developed with BioNTech SE BNTX, is given in two doses spaced three weeks apart and is approved for use those aged 16 years or older. In April, Pfizer and BioNTech had applied with U.S. and European regulators for approval to use the vaccine in 12- to 15-year olds. Pfizer shares closed up 3.1% at $39.83 Monday, while U.S. traded shares of BioNTech finished up 11%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.